Hygieia, a digital health company for insulin management, has closed on an initial $17 million Series B investment round, led by Israeli venture capital firm Firstime Ventures, and with participation from existing investors.

Hygieia will use the funding to expand partnerships with endocrinology practices and expand access to its unique d-Nav® insulin dose automation technology for people with type 2 diabetes. Currently, Hygieia has two international licenses, in Northern Ireland and in Israel. About Hygieia/ d-Nav Insulin Management ProgramHygieia is a specialty provider of insulin therapy and maker of the d-Nav® Insulin Management Program.

Digital Insulin Management Company Hygieia Closes On $17 Million Series B Investment Round

Description

Company Information

Funding Insights

Digital Insulin Management Company Hygieia Closes On $17 Million Series B Investment Round

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information